(ReliableNews.org) – A UK-based company announced plans to conduct trials for a new COVID-19 vaccine in hopes it would provide longer immunity than current inoculations and to a lesser intrusive degree than existing vaccinations.
On November 15, Oxfordshire-based Emergex Vaccines Holding Ltd announced it received the final clearance to begin Phase I clinical trials to “evaluate the safety and tolerability” of a new vaccine candidate for COVID-19. Of particular note, Emergex’s vaccine is synthetic and doesn’t introduce live viruses, DNA or RNA to humans. Instead, its CD-8 vaccines prime the body’s T-cells to quickly remove cells infected with viruses from recipients’ bodies.
UK firm to trial T-cell Covid vaccine that could give longer immunity https://t.co/74Ko54uL1l
— Guardian Science (@guardianscience) November 15, 2021
Emergex believes its vaccine will offer long-lasting immunity against all variants of SARS-CoV-1 and all SARS-CoV-2. Additionally, if successful, the vaccine won’t require any boosters. Best of all, for some recipients, the new vaccine won’t require an injection. Instead, an easy-to-use skin patch can introduce the vaccine to the body.
It could be months before the new vaccine receives final approval in the UK, provided it passes all the required trials, and even longer before the US Food and Drug Administration would grant authorization for its use in the United States.
What do you think? Would you consider taking a vaccine with emerging technology like this?
Copyright 2021, ReliableNews.org